Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

ClinicalTrials.gov ID: NCT02064426

Public ClinicalTrials.gov record NCT02064426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Controlled, Parallel Group, Open-label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Long-term Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis in the United States and Japan

Study identification

NCT ID: NCT02064426
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bayer; Industry
Enrollment: 88 participants

Conditions and interventions

Conditions

Interventions

Molidustat (BAY85-3934) Drug
Epoetin alfa/beta Biological

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 12, 2014
Primary completion: Oct 18, 2016
Completion: Nov 15, 2016
Last update posted: Sep 19, 2019

2014 – 2016

United States locations

U.S. sites: 23
U.S. states: 9
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Azusa	California	91702	—
Not listed	Long Beach	California	90813	—
Not listed	Lynwood	California	90262	—
Not listed	Northridge	California	91324	—
Not listed	San Dimas	California	91773	—
Not listed	Whittier	California	90602	—
Not listed	Whittier	California	90606	—
Not listed	New Port Richey	Florida	34652	—
Not listed	Pembroke Pines	Florida	33028	—
Not listed	Detroit	Michigan	48202	—
Not listed	Creve Coeur	Missouri	63141	—
Not listed	Buffalo	New York	14215	—
Not listed	Cincinnati	Ohio	45206	—
Not listed	Toledo	Ohio	43615	—
Not listed	Oklahoma City	Oklahoma	73116	—
Not listed	Nashville	Tennessee	37212-8150	—
Not listed	Fort Worth	Texas	76104	—
Not listed	Fort Worth	Texas	76105	—
Not listed	Fort Worth	Texas	76164	—
Not listed	Grand Prairie	Texas	75050	—
Not listed	Houston	Texas	77004	—
Not listed	Houston	Texas	77091	—
Not listed	Mansfield	Texas	76063	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02064426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 19, 2019 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02064426 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →